Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psilocybin Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

NCT06624137
View directory record Official record
Conditions
OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
Interventions
Serotonergic Psychedelic, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Hamden, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

NCT06303739
View directory record Official record
Conditions
Refractory Depression, Treatment Resistant Depression
Interventions
psilocybin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 1 Interventional

Repeat Dosing of Psilocybin in Migraine Headache

NCT04218539
View directory record Official record
Conditions
Migraine Headache
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Jul 22, 2026, 2:26 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Psilocybin in Normal Adults

NCT05467761
View directory record Official record
Conditions
Healthy
Interventions
Oral Psilocybin, IV Psilocybin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
25 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 2 Interventional

Psilocybin for Treatment-Resistant Depression

NCT06230757
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia, Treatment Resistant Depression
Interventions
Psilocybin 25mg, Placebo (active placebo)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 1Phase 2 Interventional

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout

NCT06814522
View directory record Official record
Conditions
Burnout, Burnout, Healthcare Workers
Interventions
Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 2 Interventional

Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

NCT06853912
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), PTSD
Interventions
Psilocybin 25 mg, Maltodextrin (Placebo)
Drug
Lead sponsor
Nathan Brashares Sackett
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Active, not recruiting Phase 1 Interventional

Effects of Repeated Psilocybin Dosing in OCD

NCT05370911
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Suspended Early Phase 1 Interventional Accepts healthy volunteers

Safety Profile of Psilocybin for Cocaine Use Disorder

NCT06102434
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Not yet recruiting Phase 3 Interventional

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

NCT07226232
View directory record Official record
Conditions
Major Depression
Interventions
Psilocybin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD

NCT06902974
View directory record Official record
Conditions
Post Traumatic Stress Disorder, PTSD
Interventions
Psilocybin 25 mg
Drug
Lead sponsor
Sunstone Medical
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Active, not recruiting Phase 2 Interventional

Psilocybin Therapy for Depression in Bipolar II Disorder

NCT05065294
View directory record Official record
Conditions
Bipolar II Disorder
Interventions
Psilocybin therapy
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

NCT05312151
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Rockville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Precision Functional Brain Mapping in Psilocybin

NCT04501653
View directory record Official record
Conditions
Psilocybin
Interventions
Psilocybin, Methylphenidate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Psychedelics in Healthy Older Adults With Low Well-being

NCT07386730
View directory record Official record
Conditions
Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
Interventions
Psilocybin (drug), Dextromethorphan (DXM)
Drug
Lead sponsor
Jennifer Mitchell
Other
Eligibility
50 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function

NCT07079852
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Psilocybin 15mg
Drug
Lead sponsor
Manoj Doss
Other
Eligibility
21 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

NCT01943994
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

NCT04739865
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 1 Interventional

Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD

NCT07275970
View directory record Official record
Conditions
PTSD
Interventions
Psychedelic
Drug
Lead sponsor
Suzanne "Sue" Sisley MD
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Exploratory Study of Low Dose Psilocybin

NCT05227742
View directory record Official record
Conditions
Demoralization
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

NCT05385783
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003, Psychotherapy, Placebo, Psychological Support
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
21 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

NCT04656301
View directory record Official record
Conditions
Body Dysmorphic Disorders
Interventions
Psilocybin
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Frontline Clinician Psilocybin Study

NCT05163496
View directory record Official record
Conditions
Burnout, Caregiver, Burnout, Professional, COVID-19, Depression, Post Traumatic Stress Disorder, Moral Injury
Interventions
Psilocybin (Usona Institute), Active placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

NCT04982796
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Psilocybin, Treatment-as-usual
Drug · Behavioral
Lead sponsor
Portland VA Research Foundation, Inc
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Vancouver, Washington
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 2:26 PM EDT